• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Neurocrine Biosciences - Articles and news items


Neurocrine’s Tardive Dyskinesia drug application accepted for FDA priority review

Industry news / 12 October 2016 / Niamh Louise Marriott, Digital Content Producer

The US Food and Drug Administration (FDA) has accepted for priority review the new drug application (NDA) for Neurocrine Biosciences‘ Ingrezzatm (valbenazine) for the treatment of tardive dyskinesia. The application has been given a prescription drug user fee act (PDUFA) target action date of April 11, 2017. A Priority Review designation accelerates the FDA review […]


Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +